{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:56:28Z","timestamp":1773010588090,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K23DA048182"],"award-info":[{"award-number":["K23DA048182"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["K12HS019461"],"award-info":[{"award-number":["K12HS019461"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alcohol cessation is the cornerstone of treatment for alcohol-related cirrhosis. This study evaluated associations between medical conversations about alcohol use disorder (AUD) treatment, AUD treatment engagement, and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included all patients with ICD-10 diagnosis codes for cirrhosis and AUD who were engaged in hepatology care in a single healthcare system in 2015. Baseline demographic, medical, liver disease, and AUD treatment data were assessed. AUD treatment discussions and initiation, alcohol cessation, and subsequent 5-year mortality were collected. Multivariable models were used to assess the factors associated with subsequent AUD treatment and 5-year mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 436 patients with cirrhosis due to alcohol, 65 patients (15%) received AUD treatment at baseline, including 48 (11%) receiving behavioral therapy alone, 11 (2%) receiving pharmacotherapy alone, and 6 (1%) receiving both. Over the first year after a baseline hepatology visit, 37 patients engaged in AUD treatment, 51 were retained in treatment, and 14 stopped treatment. Thirty percent of patients had hepatology-documented AUD treatment recommendations and 26% had primary care-documented AUD treatment recommendations. Most hepatology (86%) and primary care (88%) recommendations discussed behavioral therapy alone. Among patients with ongoing alcohol use at baseline, AUD treatment one year later was significantly, independently associated with AUD treatment discussions with hepatology (adjusted odds ratio (aOR): 3.23, 95% confidence interval (CI): 1.58, 6.89) or primary care (aOR: 2.95; 95% CI: 1.44, 6.15) and negatively associated with having Medicaid insurance (aOR: 0.43, 95% CI: 0.18, 0.93).\u00a0When treatment was discussed in both settings, high rates of treatment ensued (aOR: 10.72, 95% CI: 3.89, 33.52). Over a 5-year follow-up period, 152 (35%) patients died. Ongoing alcohol use, age, hepatic decompensation, and hepatocellular carcinoma were significantly associated with mortality in the final survival model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AUD treatment discussions were documented in less than half of hepatology and primary care encounters in patients with alcohol-related cirrhosis, though such discussions were significantly associated with receipt of AUD treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-023-02656-z","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T11:08:56Z","timestamp":1675336136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Alcohol treatment discussions and clinical outcomes among patients with alcohol-related cirrhosis"],"prefix":"10.1186","volume":"23","author":[{"given":"Wheytnie","family":"Alexandre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haseeb","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olufunso","family":"Agbalajobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Gmelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeyinka","family":"Adejumo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Noll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naudia L.","family":"Jonassaint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"DiMartini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8184-1546","authenticated-orcid":false,"given":"Shari S.","family":"Rogal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"issue":"8","key":"2656_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/archpsyc.61.8.807","volume":"61","author":"BF Grant","year":"2004","unstructured":"Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61(8):807\u201316.","journal-title":"Arch Gen Psychiatry"},{"issue":"1 Suppl","key":"2656_CR2","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.jhep.2015.03.006","volume":"62","author":"P Mathurin","year":"2015","unstructured":"Mathurin P, Bataller R. Trends in the management and burden of alcoholic liver disease. J Hepatol. 2015;62(1 Suppl):S38-46.","journal-title":"J Hepatol"},{"issue":"8","key":"2656_CR3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","volume":"72","author":"BF Grant","year":"2015","unstructured":"Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan WJ, Smith SM, Huang B, et al. Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiat. 2015;72(8):757\u201366.","journal-title":"JAMA Psychiat"},{"issue":"18","key":"2656_CR4","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1001\/jama.2018.16789","volume":"320","author":"SJ Curry","year":"2018","unstructured":"Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr, Kemper AR, Kubik M, et al. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(18):1899\u2013909.","journal-title":"JAMA"},{"issue":"17","key":"2656_CR5","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","volume":"295","author":"RF Anton","year":"2006","unstructured":"Anton RF, O\u2019Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003\u201317.","journal-title":"JAMA"},{"issue":"18","key":"2656_CR6","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2014.3628","volume":"311","author":"DE Jonas","year":"2014","unstructured":"Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889\u2013900.","journal-title":"JAMA"},{"issue":"1","key":"2656_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/hep.30866","volume":"71","author":"DW Crabb","year":"2020","unstructured":"Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020;71(1):306\u201333.","journal-title":"Hepatology"},{"key":"2656_CR8","doi-asserted-by":"crossref","unstructured":"Lucey MR, Im GY, Mellinger JL, Szabo G, Crabb DW. Introducing the 2019 American Association for the Study of Liver Diseases Guidance on Alcohol-Related Liver Disease. Liver Transpl 2019.","DOI":"10.1002\/lt.25600"},{"issue":"9603","key":"2656_CR9","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","volume":"370","author":"G Addolorato","year":"2007","unstructured":"Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D\u2019Angelo C, Caputo F, Zambon A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915\u201322.","journal-title":"Lancet"},{"issue":"3","key":"2656_CR10","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jhep.2016.04.029","volume":"65","author":"G Addolorato","year":"2016","unstructured":"Addolorato G, Mirijello A, Barrio P, Gual A. Treatment of alcohol use disorders in patients with alcoholic liver disease. J Hepatol. 2016;65(3):618\u201330.","journal-title":"J Hepatol"},{"issue":"4","key":"2656_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40263-013-0043-4","volume":"27","author":"G Addolorato","year":"2013","unstructured":"Addolorato G, Mirijello A, Leggio L, Ferrulli A, Landolfi R. Management of alcohol dependence in patients with liver disease. CNS Drugs. 2013;27(4):287\u201399.","journal-title":"CNS Drugs"},{"issue":"7","key":"2656_CR12","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/add.13787","volume":"112","author":"P Hauser","year":"2017","unstructured":"Hauser P, Fuller B, Ho SB, Thuras P, Kern S, Dieperink E. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial. Addiction. 2017;112(7):1173\u201383.","journal-title":"Addiction"},{"issue":"4","key":"2656_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.addbeh.2011.12.010","volume":"37","author":"L Leggio","year":"2012","unstructured":"Leggio L, Ferrulli A, Zambon A, Caputo F, Kenna GA, Swift RM, Addolorato G. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav. 2012;37(4):561\u20134.","journal-title":"Addict Behav"},{"issue":"15","key":"2656_CR14","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.2146\/ajhp140028","volume":"71","author":"CL Vuittonet","year":"2014","unstructured":"Vuittonet CL, Halse M, Leggio L, Fricchione SB, Brickley M, Haass-Koffler CL, Tavares T, Swift RM, Kenna GA. Pharmacotherapy for alcoholic patients with alcoholic liver disease. Am J Health Syst Pharm. 2014;71(15):1265\u201376.","journal-title":"Am J Health Syst Pharm"},{"issue":"8","key":"2656_CR15","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/add.14191","volume":"113","author":"AK Rose","year":"2018","unstructured":"Rose AK, Jones A. Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood: a meta-analysis. Addiction. 2018;113(8):1396\u2013406.","journal-title":"Addiction"},{"issue":"1","key":"2656_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13012-018-0795-9","volume":"13","author":"JE Glass","year":"2018","unstructured":"Glass JE, Bobb JF, Lee AK, Richards JE, Lapham GT, Ludman E, Achtmeyer C, Caldeiro RM, Parrish R, Williams EC, et al. Study protocol: a cluster-randomized trial implementing Sustained Patient-centered Alcohol-related Care (SPARC trial). Implement Sci. 2018;13(1):108.","journal-title":"Implement Sci"},{"key":"2656_CR17","doi-asserted-by":"crossref","unstructured":"Khan A, Tansel A, White DL, Kayani WT, Bano S, Lindsay J, El-Serag HB, Kanwal F: Efficacy of psychosocial interventions in inducing and maintaining alcohol abstinence in patients with chronic liver disease: a systematic review. Clin Gastroenterol Hepatol. 2016;14(2):191\u2013202. quiz e120.","DOI":"10.1016\/j.cgh.2015.07.047"},{"issue":"2","key":"2656_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/00952990.2018.1528265","volume":"45","author":"LAPD Ray","year":"2019","unstructured":"Ray LAPD, Bujarski SPD, Grodin EPD, Hartwell EPD, Green RMA, Venegas ABS, Lim AMA, Gillis AMD, Miotto KMD. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am J Drug Alcohol Abuse. 2019;45(2):124\u201340.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"6","key":"2656_CR19","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1002\/hep.31042","volume":"71","author":"S Rogal","year":"2020","unstructured":"Rogal S, Youk A, Zhang H, Gellad WF, Fine MJ, Good CB, Chartier M, DiMartini A, Morgan T, Bataller R, et al. Impact of alcohol use disorder treatment on clinical outcomes among patients with cirrhosis. Hepatology. 2020;71(6):2080\u201392.","journal-title":"Hepatology"},{"issue":"9","key":"2656_CR20","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1007\/BF02743146","volume":"21","author":"KA McCormick","year":"2006","unstructured":"McCormick KA, Cochran NE, Back AL, Merrill JO, Williams EC, Bradley KA. How primary care providers talk to patients about alcohol: a qualitative study. J Gen Intern Med. 2006;21(9):966\u201372.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"2656_CR21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s11606-017-4202-z","volume":"33","author":"EC Williams","year":"2018","unstructured":"Williams EC, Achtmeyer CE, Young JP, Berger D, Curran G, Bradley KA, Richards J, Siegel MB, Ludman EJ, Lapham GT, et al. Barriers to and facilitators of alcohol use disorder pharmacotherapy in primary care: a qualitative study in five VA clinics. J Gen Intern Med. 2018;33(3):258\u201367.","journal-title":"J Gen Intern Med"},{"key":"2656_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jsat.2018.05.003","volume":"91","author":"JL Mellinger","year":"2018","unstructured":"Mellinger JL, Scott Winder G, DeJonckheere M, Fontana RJ, Volk ML, Lok ASF, Blow FC. Misconceptions, preferences and barriers to alcohol use disorder treatment in alcohol-related cirrhosis. J Subst Abuse Treat. 2018;91:20\u20137.","journal-title":"J Subst Abuse Treat"},{"key":"2656_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jsat.2018.08.002","volume":"94","author":"D McCarty","year":"2018","unstructured":"McCarty D, Gu Y, Renfro S, Baker R, Lind BK, McConnell KJ. Access to treatment for alcohol use disorders following Oregon\u2019s health care reforms and Medicaid expansion. J Subst Abuse Treat. 2018;94:24\u20138.","journal-title":"J Subst Abuse Treat"},{"key":"2656_CR24","doi-asserted-by":"crossref","unstructured":"Mulia N, Lui CK, Bensley KMK, Subbaraman MS: Effects of Medicaid expansion on alcohol and opioid treatment admissions in U.S. racial\/ethnic groups. Drug Alcohol Depend 2022; 231:109242.","DOI":"10.1016\/j.drugalcdep.2021.109242"},{"issue":"12","key":"2656_CR25","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.jse.2013.07.051","volume":"22","author":"BM Patterson","year":"2013","unstructured":"Patterson BM, Spang JT, Draeger RW, Olsson EC, Creighton RA, Kamath GV. Access to outpatient care for adult rotator cuff patients with private insurance versus Medicaid in North Carolina. J Shoulder Elbow Surg. 2013;22(12):1623\u20137.","journal-title":"J Shoulder Elbow Surg"},{"issue":"5","key":"2656_CR26","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jaad.2012.10.034","volume":"68","author":"SB Chaudhry","year":"2013","unstructured":"Chaudhry SB, Armbrecht ES, Shin Y, Matula S, Caffrey C, Varade R, Jones L, Siegfried E. Pediatric access to dermatologists: Medicaid versus private insurance. J Am Acad Dermatol. 2013;68(5):738\u201348.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2656_CR27","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/hep.31605","volume":"73","author":"A Kardashian","year":"2021","unstructured":"Kardashian A, Wilder J, Terrault NA, Price JC. Addressing social determinants of liver disease during the COVID-19 pandemic and beyond: a call to action. Hepatology. 2021;73(2):811\u201320.","journal-title":"Hepatology"},{"issue":"1","key":"2656_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13722-019-0134-8","volume":"14","author":"EC Williams","year":"2019","unstructured":"Williams EC, Matson TE, Harris AHS. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions. Addict Sci Clin Pract. 2019;14(1):6.","journal-title":"Addict Sci Clin Pract"},{"key":"2656_CR29","doi-asserted-by":"crossref","unstructured":"Williams EC, Gupta S, Rubinsky AD, Glass JE, Jones-Webb R, Bensley KM, Harris AHS. Variation in receipt of pharmacotherapy for alcohol use disorders across racial\/ethnic groups: A national study in the U.S. Veterans Health Administration. Drug Alcohol Depend 2017, 178:527\u201333.","DOI":"10.1016\/j.drugalcdep.2017.06.011"},{"key":"2656_CR30","doi-asserted-by":"crossref","unstructured":"Woodward EN, Matthieu MM, Uchendu US, et al. The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment. Implementation Sci. 2019; 14(26).","DOI":"10.1186\/s13012-019-0861-y"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02656-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-02656-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02656-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T11:10:46Z","timestamp":1675336246000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-02656-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2656"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-02656-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1923413\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"assertion":[{"value":"7 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective cohort study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Institutional Review Board of the University of Pittsburgh approved this study under protocol number PRO16120217, with a waiver of individual informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}